Enhancing Domestic Drug Manufacturing Competitiveness Act

This bill requires the Government Accountability Office to study what rules and regulations make it harder or more expensive to build drug manufacturing facilities in the United States. The study must look at whether environmental and other regulations cause delays and higher costs, and how these rules might affect the drug supply chain. The Government Accountability Office must then report to Congress with recommendations on how to reduce these regulatory barriers and help the U.S. compete better with other countries for pharmaceutical manufacturing.

Your Vote